The dominant barrier to GLP-1 receptor agonist therapy has never been efficacy — it has been the needle. Injectable semaglutide and tirzepatide transformed obesity medicine, yet adoption remains constrained by injection aversion, cold-chain logistics, and cost. An effective oral small-molecule alternative could fundamentally democratize access to this drug class, making the ACCESS trial results genuinely consequential.
The phase 2b ACCESS trial enrolled 230 adults with a mean BMI of 39.5 kg/m² and randomized them to once-daily oral aleniglipron at three escalating dose targets — 45 mg, 90 mg, and 120 mg — or placebo over 36 weeks. The trial met its primary endpoint at every dose level. Placebo-adjusted body weight reductions reached 8.2%, 9.8%, and 11.3% at the 45-, 90-, and 120-mg arms respectively, all with p-values below 0.0001. Critically, no weight-loss plateau was apparent by week 36, and an interim analysis of the ongoing open-label extension showed continued loss beyond the blinded period. Gastrointestinal side effects, the hallmark liability of GLP-1 agents, were largely mild-to-moderate, diminished over time, and notably did not recur significantly upon dose reintroduction after permitted interruptions. Treatment-related discontinuations were 10.4%, and no drug-induced liver injury events occurred.
For context, oral semaglutide (Rybelsus) achieves roughly 5% weight loss at approved doses, constrained by peptide bioavailability challenges. Aleniglipron is a small molecule, not a peptide, which confers intrinsic oral bioavailability advantages. The 11.3% weight reduction here approaches — though does not yet match — the roughly 15% seen with injectable semaglutide 2.4 mg in the STEP trials. What distinguishes this finding is the absence of a plateau signal and the tolerability profile, both favorable for a phase 3 program. Key limitations include the modest cohort size of 230 participants, the 36-week timeframe falling short of the 68-week STEP standard, and the absence of cardiovascular outcome or diabetes subgroup data. This is an incremental but strategically important advance — less a paradigm shift than a meaningful proof of concept that oral small-molecule GLP-1 agonism at therapeutic weight-loss levels is pharmacologically achievable.